| Literature DB >> 26783408 |
Yougen Wu1, Sisay Girmay2, Vitor Martins da Silva2, Brian Perry3, Xinwen Hu4, Ghee T Tan2.
Abstract
We hypothesize that the fungal endophytes of noni may possibly play a role in its overall pharmacological repertoire, especially since the perceived efficacy of the fruit in ethnomedicinal use is associated with the fermented juice. The foremost goal of this study is to explore the role of endophyte-derived secondary metabolites in the purported anticancer properties of noni. To that end, culturable endophytic fungi resident within the healthy leaves and fruit of the plant were isolated and identified by molecular sequence analysis of the 5.8S gene and internal transcribed spacers (ITS). Purified organisms were subjected to in vitro fermentation in malt extract broth for 8 weeks under anaerobic conditions at room temperature (25°C), in order to simulate the conditions under which traditional fermented noni juice is prepared. The cytotoxic potential of organic extracts derived from the fermented broths of individual endophytes was then tested against three major cancers that afflict humans. Twelve distinct endophytic fungal species were obtained from the leaves and 3 from the fruit. Three of the leaf endophytes inhibited the growth of human carcinoma cell lines LU-1 (lung), PC-3 (prostate), and MCF-7 (breast) with IC50 values of ≤10 μg/mL.Entities:
Year: 2015 PMID: 26783408 PMCID: PMC4689921 DOI: 10.1155/2015/393960
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Culturable fungal endophytes from Morinda citrifolia Linn. (noni).
| Code | Accession number | Closest (published) Genbank match | Published | Max identity |
|---|---|---|---|---|
| Noni leaf endophytes | ||||
| MRL1-3A | KF534501 |
| AF203451 | 100% |
| MRL2-1 | KF534502 |
| EU151484 | 100% |
| MRL1-2-2 | KF534503 |
| GU566267 | 99% |
| MRL2-3 | KF534504 | Didymellaceae sp. | HM595517 | 100% |
| MRL5-1 | KF534505 | Hypocreales sp. | — | — |
| IXLP3 | KF534494 |
| AB731125 | 99% |
| VIIILP2-1 | KF534492 |
| DQ003100 | 100% |
| XILP7-2 | KF534495 |
| JQ005162 | 100% |
| VIIILP1 | KF534493 |
| JN712494 | 99% |
| XILP6 | KF534496 |
| HM189290 | 100% |
| XILP5 | KF534500 | Xylariaceae sp. | JX852331 | 95% |
| XIILP3-1 | KF534498 |
| EF652507 | 100% |
| Noni fruit endophytes | ||||
| XSM1 | KF534499 |
| JQ518278 | 94% |
| VIIIfP1 | KF534497 |
| AB303549 | 99% |
| IIfP | KF534491 |
| GQ352478 | 99% |
Cytotoxic activities (IC50) of fungal endophyte extracts against three human cancer cell lines.
| Code | Genbank match | Order > family | IC50 ( | ||
|---|---|---|---|---|---|
| LU-1[b] | MCF-7[c] | PC-3[d] | |||
| Noni leaf endophytes | |||||
| MRL1-3A |
| Pleosporales > Pleosporaceae |
|
|
|
| MRL2-1 |
| Hypocreales > Nectriaceae | >50 | >50 | >50 |
| MRL1-2-2 |
| Hypocreales > Hypocreaceae | >50 | >50 | >50 |
| MRL2-3 | Didymellaceae sp. | Pleosporales > Didymellaceae | >50 | >50 | >50 |
| MRL5-1 | Hypocreales sp. | Hypocreales | >50 | >50 | >50 |
| IXLP3 |
| Botryosphaeriales > Botryosphaeriaceae | >50 | >50 | >50 |
| VIIILP2-1 |
| Glomerellales > Glomerellaceae | >50 | >50 | >50 |
| XILP7-2 |
| Glomerellales > Glomerellaceae | >50 | >50 | >50 |
| VIIILP1 |
| Pleosporales > Didymellaceae |
|
|
|
| XILP6 |
| Capnodiales > Mycosphaerellaceae | >50 | >50 | >50 |
| XILP5 | Xylariaceae sp. | Xylariales > Xylariaceae |
|
|
|
| XIILP3-1 |
| Eurotiales > Trichocomaceae | >50 | >50 | >50 |
| Noni fruit endophytes | |||||
| XSM1 |
| Polyporales > Phanerochaetaceae | >50 | >50 | >50 |
| VIIIfP1 |
| Pleosporales > Montagnulaceae | >50 | >50 | >50 |
| IIfP |
| Diaporthales > Valsaceae | >50 | >50 | >50 |
| Positive control | 0.02 ± 0.001 | 0.05 ± 0.002 | 0.3 ± 0.012 | ||
[a]The IC50 value is defined as the concentration of extract required to produce 50% reduction in viability compared to the standard cytotoxic agent, ellipticine. All fungal extracts were tested in triplicate, and IC50 values were calculated from the mean dose-response curves. IC50 values represent the average over triplicate experiments performed with three successive passages of the same endophyte.
[b]LU-1, human lung adenocarcinoma.
[c]MCF-7, human mammary adenocarcinoma.
[d]PC-3, human prostate adenocarcinoma.